OrphanDrug
OrphanDrug
Pharma Knowledge Base

hypomyelination-hypogonadotropic hypogonadism-hypodontia syndrome

ORPHA: 88637

Contents

  1. 1. Overview
  2. 2. Available Treatments
  3. 3. Clinical Presentation
  4. 4. Classification & Codes

Overview

Hypomyelination-hypogonadotropic hypogonadism-hypodontia syndrome is characterised by the association of demyelinating leukodystrophy with progressive cerebellar ataxia, hypogonadotropic hypogonadism and hypodontia

Available Treatments (0)

No treatments linked yet

Clinical trials or compassionate use may be available — consult a specialist.

Clinical Presentation

Signs and symptoms associated with hypomyelination-hypogonadotropic hypogonadism-hypodontia syndrome, sourced from HPO and Orphanet clinical annotations.

HypodontiaHypergonadotropic hypogonadismAtaxiaCNS hypomyelination

Classification & Codes

Orphanet Code

ORPHA:88637
hypomyelination-hypogonadotropic hypogonadism-hypodontia syndrome
OrphanetORPHA:88637
Treatments0 drug(s)
Symptoms on record4 signs
Statuspublished
Factual Authority
Last Updated3/20/2026
Clinical DataHPO · Orphanet
Drug DataFDA · EMA · CDSCO